Molecular BiologybioRxivPreprint
CRISPR/Cas13-mediated Dynamin 2 reduction therapy in a canine model of DNM2-related centronuclear myopathy
Andrea Carlier, Inès Barthélémy, Nicolas Blanchard‐Gutton…·Isabel Punzón
This study demonstrates that CRISPR/Cas13-mediated reduction of DNM2 expression can alleviate CNM symptoms in a canine model.
DOI 10.1101/2025.09.05.672814